Do analysts recommend CGC or LIXT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer CGC or LIXT?

In the previous week, Canopy Growth had 1 more articles in the media than Lixte Biotechnology. MarketBeat recorded 7 mentions for Canopy Growth and 6 mentions for Lixte Biotechnology. Canopy Growth's average media sentiment score of 1.34 beat Lixte Biotechnology's score of 0.02 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lixte Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend LIXT or OCGN?

Ocugen has a consensus price target of $9.50, indicating a potential upside of 685.12%. Given Ocugen's stronger consensus rating and higher possible upside, analysts clearly believe Ocugen is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ocugen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Is LIXT or OCGN more profitable?

Lixte Biotechnology has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Lixte Biotechnology's return on equity of -134.91% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -134.91% -95.61% Ocugen -1,192.18% -127,987.80% -135.48%

Do analysts recommend LIXT or MNPR?

Monopar Therapeutics has a consensus price target of $107.91, indicating a potential upside of 80.54%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Monopar Therapeutics is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Monopar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has stronger valuation & earnings, LIXT or MNPR?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lixte Biotechnology N/A N/A -$6.01M -$1.13 N/A Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A

Is LIXT or MNPR more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -134.91% -95.61% Monopar Therapeutics N/A -12.84% -12.57%

Does the media prefer LIXT or MNPR?

In the previous week, Lixte Biotechnology had 4 more articles in the media than Monopar Therapeutics. MarketBeat recorded 6 mentions for Lixte Biotechnology and 2 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.41 beat Lixte Biotechnology's score of 0.02 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer LIXT or AUTL?

Autolus Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 460.90%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Autolus Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89

Does the media favor LIXT or AUTL?

In the previous week, Lixte Biotechnology had 2 more articles in the media than Autolus Therapeutics. MarketBeat recorded 6 mentions for Lixte Biotechnology and 4 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.30 beat Lixte Biotechnology's score of 0.02 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Autolus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, EPRX or LIXT?

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A Lixte Biotechnology N/A N/A -$6.01M -$1.13 N/A

Is EPRX or LIXT more profitable?

Eupraxia Pharmaceuticals' return on equity of -87.56% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -87.56% -51.20% Lixte Biotechnology N/A -134.91% -95.61%

Does the media refer more to EPRX or LIXT?

In the previous week, Lixte Biotechnology had 3 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 6 mentions for Lixte Biotechnology and 3 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.62 beat Lixte Biotechnology's score of 0.02 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lixte Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lixte Biotechnology (LIXT) Competitors

$6.19 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$6.42 +0.23 (+3.80%)

As of 06/12/2026 05:23 PM Eastern

Compare

LIXT vs. CGC, OCGN, MNPR, AUTL, and EPRX

Should you buy Lixte Biotechnology stock or one of its competitors? MarketBeat compares Lixte Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lixte Biotechnology include Canopy Growth (CGC), Ocugen (OCGN), Monopar Therapeutics (MNPR), Autolus Therapeutics (AUTL), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry.

How does Lixte Biotechnology compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Lixte Biotechnology has a net margin of 0.00% compared to Canopy Growth's net margin of -94.39%. Canopy Growth's return on equity of -46.85% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-94.39%	-46.85%	-28.95%
Lixte Biotechnology	N/A	-134.91%	-95.61%

3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Comparatively, 9.5% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Canopy Growth had 1 more articles in the media than Lixte Biotechnology. MarketBeat recorded 7 mentions for Canopy Growth and 6 mentions for Lixte Biotechnology. Canopy Growth's average media sentiment score of 1.34 beat Lixte Biotechnology's score of 0.02 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lixte Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lixte Biotechnology has lower revenue, but higher earnings than Canopy Growth. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$225.65M	1.79	-$429.86M	-$1.30	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

Canopy Growth has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Summary

Canopy Growth beats Lixte Biotechnology on 8 of the 14 factors compared between the two stocks.

How does Lixte Biotechnology compare to Ocugen?

Lixte Biotechnology (NASDAQ:LIXT) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Lixte Biotechnology has higher earnings, but lower revenue than Ocugen. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Ocugen	$4.41M	92.88	-$67.85M	-$0.24	N/A

Lixte Biotechnology has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Lixte Biotechnology's return on equity of -134.91% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Ocugen	-1,192.18%	-127,987.80%	-135.48%

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 9.5% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 4.0% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Lixte Biotechnology had 5 more articles in the media than Ocugen. MarketBeat recorded 6 mentions for Lixte Biotechnology and 1 mentions for Ocugen. Ocugen's average media sentiment score of 1.89 beat Lixte Biotechnology's score of 0.02 indicating that Ocugen is being referred to more favorably in the news media.

Company	Overall Sentiment
Lixte Biotechnology	Neutral
Ocugen	Very Positive

Ocugen has a consensus price target of $9.50, indicating a potential upside of 685.12%. Given Ocugen's stronger consensus rating and higher possible upside, analysts clearly believe Ocugen is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Lixte Biotechnology has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.2, indicating that its share price is 120% more volatile than the broader market.

Summary

Ocugen beats Lixte Biotechnology on 9 of the 15 factors compared between the two stocks.

How does Lixte Biotechnology compare to Monopar Therapeutics?

Lixte Biotechnology (NASDAQ:LIXT) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

5.1% of Lixte Biotechnology shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 9.5% of Lixte Biotechnology shares are held by insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Monopar Therapeutics has a consensus price target of $107.91, indicating a potential upside of 80.54%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Monopar Therapeutics is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Monopar Therapeutics' return on equity of -12.84% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Monopar Therapeutics	N/A	-12.84%	-12.57%

In the previous week, Lixte Biotechnology had 4 more articles in the media than Monopar Therapeutics. MarketBeat recorded 6 mentions for Lixte Biotechnology and 2 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.41 beat Lixte Biotechnology's score of 0.02 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lixte Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monopar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

Lixte Biotechnology has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Summary

Monopar Therapeutics beats Lixte Biotechnology on 9 of the 14 factors compared between the two stocks.

How does Lixte Biotechnology compare to Autolus Therapeutics?

Lixte Biotechnology (NASDAQ:LIXT) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Lixte Biotechnology has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market.

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 9.5% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lixte Biotechnology has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Autolus Therapeutics' return on equity of -128.59% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

Autolus Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 460.90%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

In the previous week, Lixte Biotechnology had 2 more articles in the media than Autolus Therapeutics. MarketBeat recorded 6 mentions for Lixte Biotechnology and 4 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.30 beat Lixte Biotechnology's score of 0.02 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lixte Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Autolus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lixte Biotechnology has higher earnings, but lower revenue than Autolus Therapeutics. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Autolus Therapeutics	$75.39M	5.51	-$287.53M	-$1.09	N/A

Summary

Autolus Therapeutics beats Lixte Biotechnology on 13 of the 16 factors compared between the two stocks.

How does Lixte Biotechnology compare to Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

Eupraxia Pharmaceuticals presently has a consensus price target of $18.33, indicating a potential upside of 203.53%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lixte Biotechnology had 3 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 6 mentions for Lixte Biotechnology and 3 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.62 beat Lixte Biotechnology's score of 0.02 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lixte Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eupraxia Pharmaceuticals' return on equity of -87.56% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
Lixte Biotechnology	N/A	-134.91%	-95.61%

5.1% of Lixte Biotechnology shares are owned by institutional investors. 9.5% of Lixte Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Eupraxia Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Summary

Eupraxia Pharmaceuticals beats Lixte Biotechnology on 8 of the 14 factors compared between the two stocks.

Get Lixte Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIXT vs. The Competition

Export

Metric	Lixte Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$92.97M	$3.39B	$6.53B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-5.48	20.00	23.99	24.42
Price / Sales	N/A	306.82	513.41	111.24
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	5.90	8.32	10.73	6.82
Net Income	-$6.01M	$23.94M	$3.57B	$337.56M
7 Day Performance	-6.92%	1.84%	0.59%	1.17%
1 Month Performance	19.96%	-0.04%	1.54%	3.16%
1 Year Performance	442.98%	44.82%	25.42%	30.58%

Lixte Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIXT Lixte Biotechnology	0.2612 of 5 stars	$6.19 flat	N/A	+443.0%	$92.97M	N/A	N/A	4	Analyst Upgrade Gap Up High Trading Volume
CGC Canopy Growth	1.9047 of 5 stars	$1.01 -1.0%	N/A	-32.4%	$408.16M	$225.65M	N/A	3,150	Positive News Gap Up
OCGN Ocugen	2.1279 of 5 stars	$1.19 -4.0%	$9.50 +698.3%	+7.1%	$402.84M	$4.41M	N/A	80	Positive News
MNPR Monopar Therapeutics	2.0083 of 5 stars	$59.42 -2.0%	$107.91 +81.6%	+78.3%	$398.11M	N/A	N/A	10	News Coverage Analyst Downgrade
AUTL Autolus Therapeutics	3.7861 of 5 stars	$1.48 +1.4%	$8.75 +491.2%	-26.4%	$393.92M	$75.39M	N/A	330	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIXT) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lixte Biotechnology (LIXT) Competitors

LIXT vs. CGC, OCGN, MNPR, AUTL, and EPRX

How does Lixte Biotechnology compare to Canopy Growth?

Summary

How does Lixte Biotechnology compare to Ocugen?

Summary

How does Lixte Biotechnology compare to Monopar Therapeutics?

Summary

How does Lixte Biotechnology compare to Autolus Therapeutics?

Summary

How does Lixte Biotechnology compare to Eupraxia Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIXT vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lixte Biotechnology (LIXT) Competitors

LIXT vs. CGC, OCGN, MNPR, AUTL, and EPRX

How does Lixte Biotechnology compare to Canopy Growth?

Is CGC or LIXT more profitable?

Do institutionals and insiders hold more shares of CGC or LIXT?

Does the media prefer CGC or LIXT?

Do analysts recommend CGC or LIXT?

Which has better valuation & earnings, CGC or LIXT?

Which has more risk & volatility, CGC or LIXT?

Summary

How does Lixte Biotechnology compare to Ocugen?

Which has better valuation & earnings, LIXT or OCGN?

Is LIXT or OCGN more profitable?

Do institutionals & insiders have more ownership in LIXT or OCGN?

Does the media favor LIXT or OCGN?

Do analysts recommend LIXT or OCGN?

Which has more volatility & risk, LIXT or OCGN?

Summary

How does Lixte Biotechnology compare to Monopar Therapeutics?

Do institutionals and insiders believe in LIXT or MNPR?

Do analysts recommend LIXT or MNPR?

Is LIXT or MNPR more profitable?

Does the media prefer LIXT or MNPR?

Which has stronger valuation & earnings, LIXT or MNPR?

Which has more volatility and risk, LIXT or MNPR?

Summary

How does Lixte Biotechnology compare to Autolus Therapeutics?

Which has more risk and volatility, LIXT or AUTL?

Do institutionals and insiders hold more shares of LIXT or AUTL?

Is LIXT or AUTL more profitable?

Do analysts prefer LIXT or AUTL?

Does the media favor LIXT or AUTL?

Which has preferable earnings and valuation, LIXT or AUTL?

Summary

How does Lixte Biotechnology compare to Eupraxia Pharmaceuticals?

Which has stronger valuation and earnings, EPRX or LIXT?

Do analysts recommend EPRX or LIXT?

Does the media refer more to EPRX or LIXT?

Is EPRX or LIXT more profitable?

Do insiders and institutionals have more ownership in EPRX or LIXT?

Which has more volatility & risk, EPRX or LIXT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIXT vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools